Galectin Therapeutics Inc.
DE ˙ DB ˙ US3632252025
1,88 € ↓ -0,05 (-2,59%)
2026-06-03
AKTIENPREIS
SecurityDE:PHPN / Galectin Therapeutics Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership130,448 shares
Latest Disclosed Value $ 363,950
Northern Trust Corp ownership in PHPN / Galectin Therapeutics Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 130,448 shares of Galectin Therapeutics Inc. (DE:PHPN) valued at $292,204 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 130,448 shares of Galectin Therapeutics Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $245,242 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 130,448 0 0.00 364 -33.03 0.0000
2026-02-17 2025-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 130,448 9,383 7.75 543 5.86 0.0001
2025-11-14 2025-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 121,065 324 0.27 513 101.57 0.0001
2025-08-13 2025-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 120,741 -49,486 -29.07 255 22.71 0.0000
2025-05-13 2025-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 170,227 -74,047 -30.31 208 -34.29 0.0000
2025-02-14 2024-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 244,274 9,994 4.27 315 -51.09 0.0000
2024-11-13 2024-09-30 13F GALECTIN THERAPEUTICS COM 363225202 234,280 107,306 84.51 644 125.17 0.0001
2024-08-14 2024-06-30 13F GALECTIN THERAPEUTICS COM 363225202 126,974 25,823 25.53 287 18.67 0.0000
2024-05-14 2024-03-31 13F GALECTIN THERAPEUTICS COM 363225202 101,151 129 0.13 242 44.31 0.0000
2024-02-13 2023-12-31 13F GALECTIN THERAPEUTICS COM 363225202 101,022 -942 -0.92 168 -14.36 0.0000
2023-11-13 2023-09-30 13F GALECTIN THERAPEUTICS COM 363225202 101,964 0 0.00 196 33.56 0.0000
2023-08-11 2023-06-30 13F GALECTIN THERAPEUTICS COM 363225202 101,964 7,206 7.60 147 -26.26 0.0000
2023-05-15 2023-03-31 13F GALECTIN THERAPEUTICS COM 363225202 94,758 9,895 11.66 199 108.42 0.0000
2023-02-13 2022-12-31 13F GALECTIN THERAPEUTICS COM 363225202 84,863 -390 -0.46 96 -31.65 0.0000
2022-11-14 2022-09-30 13F GALECTIN THERAPEUTICS COM 363225202 85,253 -4,608 -5.13 139 17.80 0.0000
2022-08-12 2022-06-30 13F GALECTIN THERAPEUTICS COM 363225202 89,861 -3,677 -3.93 118 -21.33 0.0000
2022-05-13 2022-03-31 13F GALECTIN THERAPEUTICS COM 363225202 93,538 -450 -0.48 150 -22.68 0.0000
2022-02-08 2021-12-31 13F GALECTIN THERAPEUTICS COM 363225202 93,988 5,168 5.82 194 -43.77 0.0000
2021-11-15 2021-09-30 13F GALECTIN THERAPEUTICS COM 363225202 88,820 -7,450 -7.74 345 11.65 0.0001
2021-08-13 2021-06-30 13F GALECTIN THERAPEUTICS COM 363225202 96,270 -324,833 -77.14 309 -66.16 0.0001
2021-05-12 2021-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 421,103 -31,854 -7.03 913 -9.96 0.0002
2021-02-11 2020-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 452,957 -13,007 -2.79 1,014 -18.55 0.0002
2020-11-16 2020-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 465,964 -28,385 -5.74 1,245 -17.66 0.0003
2020-08-14 2020-06-30 13F GALECTIN THERAPEUTICS COM 363225202 494,349 -22,685 -4.39 1,512 49.26 0.0004
2020-05-14 2020-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 517,034 26,722 5.45 1,013 -27.75 0.0003
2020-02-14 2019-12-31 13F GALECTIN THERAPEUTICS COM 363225202 490,312 874 0.18 1,402 -21.98 0.0003
2019-11-13 2019-09-30 13F GALECTIN THERAPEUTICS COM 363225202 489,438 355,322 264.94 1,797 223.20 0.0004
2019-08-13 2019-06-30 13F GALECTIN THERAPEUTICS COM 363225202 134,116 44,345 49.40 556 21.40 0.0001
2019-05-13 2019-03-31 13F GALECTIN THERAPEUTICS COM 363225202 89,771 2,839 3.27 458 53.69 0.0001
2019-02-12 2018-12-31 13F GALECTIN THERAPEUTICS COM 363225202 86,932 -953 -1.08 298 -43.67 0.0001
2018-11-14 2018-09-30 13F GALECTIN THERAPEUTICS COM 363225202 87,885 1,267 1.46 529 -3.99 0.0001
2018-09-18 2018-06-30 13F/A-1 GALECTIN THERAPEUTICS COM 363225202 86,618 7,362 9.29 551 46.54 0.0001
2018-08-14 2018-06-30 13F GALECTIN THERAPEUTICS COM 363225202 86,618 7,362 551
2018-05-09 2018-03-31 13F GALECTIN THERAPEUTICS COM 363225202 79,256 -4,412 -5.27 376 34.77 0.0001
2018-02-14 2017-12-31 13F GALECTIN THERAPEUTICS COM 363225202 83,668 2,929 3.63 279 61.27 0.0001
2017-11-13 2017-09-30 13F GALECTIN THERAPEUTICS COM 363225202 80,739 5,642 7.51 173 -6.49 0.0000
2017-08-11 2017-06-30 13F GALECTIN THERAPEUTICS COM 363225202 75,097 3,176 4.42 185 12.12 0.0001
2017-05-12 2017-03-31 13F GALECTIN THERAPEUTICS COM 363225202 71,921 26,716 59.10 165 275.00 0.0000
2017-02-13 2016-12-31 13F GALECTIN THERAPEUTICS COM 363225202 45,205 1,978 4.58 44 -10.20 0.0000
2016-11-09 2016-09-30 13F GALECTIN THERAPEUTICS COM 363225202 43,227 0 0.00 49 -22.22 0.0000
2016-08-12 2016-06-30 13F GALECTIN THERAPEUTICS COM 363225202 43,227 4,250 10.90 63 12.50 0.0000
2016-08-19 2016-03-31 13F/A-1 GALECTIN THERAPEUTICS COM 363225202 38,977 -3,995 -9.30 56 -21.13 0.0000
2016-05-13 2016-03-31 13F GALECTIN THERAPEUTICS COM 363225202 38,977 56
2016-02-12 2015-12-31 13F GALECTIN THERAPEUTICS COM 363225202 42,972 -21,650 -33.50 71 -52.98 0.0000
2015-11-12 2015-09-30 13F GALECTIN THERAPEUTICS COM 363225202 64,622 -117,855 -64.59 151 -69.68 0.0001
2015-08-13 2015-06-30 13F GALECTIN THERAPEUTICS COM 363225202 182,477 -21,787 -10.67 498 -27.19 0.0003
2015-05-14 2015-03-31 13F GALECTIN THERAPEUTICS COM 363225202 204,264 433 0.21 684 -3.25 0.0002
2015-02-12 2014-12-31 13F GALECTIN THERAPEUTICS COM 363225202 203,831 -2,563 -1.24 707 -31.89 0.0002
2014-11-13 2014-09-30 13F GALECTIN THERAPEUTICS COM 363225202 206,394 142,337 222.20 1,038 17.29 0.0003
2014-08-14 2014-06-30 13F GALECTIN THERAPEUTICS COM 363225202 64,057 23,815 59.18 885 43.67 0.0003
2014-05-14 2014-03-31 13F GALECTIN THERAPEUTICS COM 363225202 40,242 4,825 13.62 616 115.38 0.0002
2014-02-21 2013-12-31 13F/A-1 GALECTIN THERAPEUTICS COM 363225202 35,417 3,302 10.28 286 -10.62 0.0001
2014-02-12 2013-12-31 13F GALECTIN THERAPEUTICS COM 363225202 35,417 286
2013-11-13 2013-09-30 13F GALECTIN THERAPEUTICS COM 363225202 32,115 32,115 320 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.